The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schrier, R. D.
Right arrow Articles by Nelson, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schrier, R. D.
Right arrow Articles by Nelson, J. A.

The Journal of Immunology, Vol 142, Issue 4 1166-1176, Copyright © 1989 by American Association of Immunologists


ARTICLES

T cell recognition of HIV synthetic peptides in a natural infection

RD Schrier, JW Gnann Jr, R Landes, C Lockshin, D Richman, A McCutchan, C Kennedy, MB Oldstone and JA Nelson
Department of Immunology, Research Institute of Scripps Clinic, La Jolla, CA 92037.

Because T cell responses are critical for defense against viral infections, a series of synthetic peptides derived from the predicted sequence for HIV-1 proteins gp41, pg120, gag, and viral polymerase were used to test the T cell proliferative response of HIV-1 seropositive individuals. Of HIV-1-infected donors from various clinical categories 90% (27/30) had sensitized cells that proliferated in response to at least one of 21 HIV peptides tested. Cells from HIV seronegative controls did not proliferate (0/9) in response to these HIV peptides. Individuals with fewer clinical manifestations of HIV-1 disease responded to a greater number of peptides (average for asymptomatic seropositives = 8.1 peptides; AIDS patients averaged 2.0). The number of peptides recognized also correlated with absolute number of CD4+ cells, but not with delayed cutaneous hypersensitivity to a (non-HIV) battery of Ag. However, clinical stage at no time correlated with the response to any particular peptide. Response patterns differed considerably among individuals, and some peptides stimulated proliferation in many (48%) HIV-infected donors (peptides gp41-2 and pol-3), whereas another peptide elicited no T cell response in any donor tested (peptide gp120-8). We have also begun to investigate the basis for individual heterogeneity of T lymphocyte proliferative responses of HIV-infected donors to the 21 HIV synthetic peptides. Peptide structure and HLA class II determinants both influenced patterns of lymphocyte responses. Reactivity correlated with peptide size, the presence of alpha and beta secondary structure and lack of reverse turn potential. Hydropathy and charge had no predictive value. Peptides derived from HIV sequences that vary highly among strains tended to be recognized less frequently. HIV-infected lymphocyte donors were HLA typed to examine the influence of the MHC on T lymphocyte proliferation. Analysis of the frequencies of individuals reacting to specific peptides, when compared to the allele frequencies in the population at large, indicated association of some responses to DR alleles. More DR association was observed with peptides that showed "moderate" reactivity than with those that were "highly" reactive. We suggest that highly reactive peptides are capable of forming a structure closer to an "ideal" T cell epitope that can associate with many DR alleles. In contrast, "moderately" reactive determinants have less favorable structures for interaction, are more limited in their ability to interact and therefore show more restriction to specific class II alleles.


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
G. Dai, N. K. Steede, and S. J. Landry
Allocation of Helper T-cell Epitope Immunodominance According to Three-dimensional Structure in the Human Immunodeficiency Virus Type I Envelope Glycoprotein gp120
J. Biol. Chem., November 2, 2001; 276(45): 41913 - 41920.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
C. C. Wilson, B. Palmer, S. Southwood, J. Sidney, Y. Higashimoto, E. Appella, R. Chesnut, A. Sette, and B. D. Livingston
Identification and Antigenicity of Broadly Cross-Reactive and Conserved Human Immunodeficiency Virus Type 1-Derived Helper T-Lymphocyte Epitopes
J. Virol., May 1, 2001; 75(9): 4195 - 4207.
[Abstract] [Full Text]


Home page
ScienceHome page
E. S. Rosenberg, J. M. Billingsley, A. M. Caliendo, S. L. Boswell, P. E. Sax, S. A. Kalams, and B. D. Walker
Vigorous HIV-1-Specific CD4+ T Cell Responses Associated with Control of Viremia
Science, November 21, 1997; 278(5342): 1447 - 1450.
[Abstract] [Full Text]


Home page
J. Exp. Med.Home page
R. P. Johnson
Upregulation of Fas Ligand by Simian Immunodeficiency Virus---A nef-arious Mechanism of Immune Evasion?
J. Exp. Med., July 7, 1997; 186(1): 1 - 5.
[Full Text] [PDF]


Home page
ScienceHome page
A. Hugin, M. Vacchio, and H. Morse 3rd
A virus-encoded "superantigen" in a retrovirus-induced immunodeficiency syndrome of mice
Science, April 19, 1991; 252(5004): 424 - 427.
[Abstract] [PDF]


Home page
ScienceHome page
R. Orentas, J. Hildreth, E Obah, M Polydefkis, G. Smith, M. Clements, and R. Siliciano
Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine
Science, June 8, 1990; 248(4960): 1234 - 1237.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1989 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1989 by The American Association of Immunologists, Inc. All rights reserved.